C-reactive protein levels, blood pressure and the risks of gestational hypertensive complications: The Generation R Study

Journal of Hypertension

Volumn 29, Issue 12, 2011, Pages 2413-2421

  De Jonge, Layla L ^a,b   Steegers, Eric A P ^b   Ernst, Gesina D S ^a,b   Lindemans, Jan ^b   Russcher, Henk ^b   Hofman, Albert ^b   Jaddoe, Vincent W V ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Department of Epidemiology ^*  (Netherlands)

Author keywords

Blood pressure; C reactive protein; preeclampsia; pregnancyinduced hypertension

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECLAMPSIA; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HELLP SYNDROME; HIGH RISK PATIENT; HISTOPATHOLOGY; HOSPITAL; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MEDICAL RECORD; MOTHER; NETHERLANDS; POPULATION BASED CASE CONTROL STUDY; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE;

EID: 81355160324     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834c58e5     Document Type: Article

References (36)

1. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: A systematic review. Lancet 2006; 367:1066-1074.
2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. Lancet 2010; 376:631-644.
3. Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am. J. Hypertens 1991; 4:700-708.
4. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am. J. Obstet Gynecol 1998; 179:80-86.
5. Redman CW, Sacks GP, Sargent IL. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am. J. Obstet Gynecol 1999; 180:499-506.
6. AbliJ. H, Meinders A. C-reactive protein: history and revival. Eur J. Intern Med 2002; 13:412.
7. Kluft C, de Maat MP. Sensitive markers of inflammation make it possible to study the chronic process: The rise of interest in low levels of C-reactive protein. Vascul Pharmacol 2002; 39:99-104.
8. von Versen-Hoeynck FM, Hubel CA, Gallaher MJ, Gammill HS, Powers RW. Plasma levels of inflammatory markers neopterin, sialic acid, and C-reactive protein in pregnancy and preeclampsia. Am. J. Hypertens 2009; 22:687-692.
9. Tjoa ML, van Vugt JM, Go AT, Blankenstein MA, Oudejans CB, van Wijk IJ. Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. J. Reproduct Immunol 2003; 59:29-37.
10. Qiu C, Luthy DA, Zhang C, Walsh SW, Leisenring WM, Williams MA. A prospective study of maternal serum C-reactive protein concentrations and risk of preeclampsia. Am. J. Hypertens 2004; 17:154-160.
11. Ustun Y, Engin-Ustun Y, Kamaci M. Association of fibrinogen and C-reactive protein with severity of preeclampsia. Eur J. Obstet Gynecol Reprod Biol 2005; 121:154-158.
12. Hwang HS, Kwon JY, Kim MA, Park YW, Kim YH. Maternal serum highly sensitive C-reactive protein in normal pregnancy and preeclampsia. Int J. Gynaecol Obstet 2007; 98:105-109.
13. Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Obesity and preeclampsia: The potential role of inflammation. Obstet Gynecol 2001; 98:757-762.
14. Garcia RG, Celedon J, Sierra-Laguado J, Alarcon MA, Luengas C, Silva F, et al. Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia. Am. J. Hypertens 2007; 20:98-103.
15. Savvidou MD, Lees CC, Parra M, Hingorani AD, Nicolaides KH. Levels of C-reactive protein in pregnant women who subsequently develop preeclampsia. BJOG 2002; 109:297-301.
16. Cebesoy FB, Balat O, Dikensoy E, Kalayci H, Ibar Y. CA-125 and CRP are elevated in preeclampsia. Hypertens Pregnancy 2009; 28:201-211.
17. Bertran N, Camps J, Fernandez-Ballart J, Murphy MM, Arija V, Ferre N, et al. Evaluation of a high-sensitivity turbidimetric immunoassay for serum C-reactive protein: Application to the study of longitudinal changes throughout normal pregnancy. Clin Chem Lab Med 2005; 43:308-313.
18. Madan JC, Davis JM, Craig WY, Collins M, Allan W, Quinn R, Dammann O. Maternal obesity and markers of inflammation in pregnancy. Cytokine 2009; 47:61-64.
19. Jaddoe VW, Bakker R, van Duijn CM, van der Heijden AJ, Lindemans J, Mackenbach JP, et al. The Generation R Study Biobank: A resource for epidemiological studies in children and their parents. Eur J. Epidemiol 2007; 22:917-923.
20. Jaddoe VW, van Duijn CM, van der Heijden AJ, Mackenbach JP, Moll HA, Steegers EA, et al. The Generation R Study: design and cohort update 2010. Eur J. Epidemiol 2010; 25:823-841.
21. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, Rifai N. Evaluation of nine automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Part 2. Clin Chem 2001; 47:418-425.
22. Ernst GD, de Jonge LL, Hofman A, Lindemans J, Russcher H, Steegers EA, Jaddoe VW. C-reactive protein levels in early pregnancy, fetal growth patterns, and the risk for neonatal complications: The Generation R Study. Am. J. Obstet Gynecol 2011; 205:132.e1-e12.
23. El Assaad MA, Topouchian JA, Darne BM, Asmar RG. Validation of the Omron HEM-907 device for blood pressure measurement. Blood Press Monit 2002; 7:237-241.
24. Coolman M, de Groot CJ, Jaddoe VW, Hofman A, Raat H, Steegers EA. Medical record validation of maternally reported history of preeclampsia. J. Clin Epidemiol 2010; 63:932-937.
25. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-XIV.
26. Goldstein H. Multilevel statistical methods, 2nd ed. London: Edward Arnold; 1995.
27. Bakker R, Steegers EA, Mackenbach JP, Hofman A, Jaddoe VW. Maternal smoking and blood pressure in different trimesters of pregnancy: The Generation R study. J. Hypertens 2010; 28:2210-2218.
28. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007; 16:219-242.
29. Redman CW, Sargent IL. Preeclampsia and the systemic inflammatory response. Semin Nephrol 2004; 24:565-570.
30. Sacks GP, Seyani L, Lavery S, Trew G. Maternal C-reactive protein levels are raised at 4 weeks gestation. Hum Reprod 2004; 19:1025-1030.
31. Hermida RC, Ayala DE, Iglesias M. Predictable blood pressure variability in healthy and complicated pregnancies. Hypertension 2001; 38:736-741.
32. Gaillard R, Steegers EA, Hofman A, Jaddoe VW. Associations of maternal obesity with blood pressure and the risks of gestational hypertensive disorders: The Generation R Study. J. Hypertens 2011; 29:937-944.
33. Bodnar LM, Ness RB, Harger GF, Roberts JM. Inflammation and triglycerides partially mediate the effect of prepregnancy body mass index on the risk of preeclampsia. Am. J. Epidemiol 2005; 162:1198-1206.
34. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945-2951.
35. Ross R. Atherosclerosis: An inflammatory disease. N Engl J. Med 1999; 340:115-126.
36. Todd ME. Hypertensive structural changes in blood vessels: do endothelial cells hold the key? Can J. Physiol Pharmacol 1992; 70:536-551.